CHI Advisors
Latest statistics and disclosures from CHI Advisors's latest quarterly 13F-HR filing:
- Top 5 stock holdings are PLRX, RPTX, CGEM, SLRN, Orchard Therapeutics, and represent 62.35% of CHI Advisors's stock portfolio.
- Added to shares of these 10 stocks: Orchard Therapeutics (+$13M), MLYS (+$5.4M), BPMC, RARE, MLTX, SGMT, SYRS, TSVT, INZY, Freeline Therapeutics Holdings.
- Started 4 new stock positions in MLYS, BPMC, SGMT, MLTX.
- Reduced shares in these 10 stocks: Vectivbio Hldg (-$47M), IRON, SLRN, LABD, PLRX, Hookipa Pharma Inc equity, RLYB, CRVS, Precision Biosciences Ord, BDTX.
- Sold out of its positions in CRVS, Hookipa Pharma Inc equity, Vectivbio Hldg.
- CHI Advisors was a net seller of stock by $-23M.
- CHI Advisors has $255M in assets under management (AUM), dropping by -23.11%.
- Central Index Key (CIK): 0001791468
Tip: Access up to 7 years of quarterly data
Positions held by CHI Advisors consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for CHI Advisors
CHI Advisors holds 26 positions in its portfolio as reported in the September 2023 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Pliant Therapeutics (PLRX) | 21.4 | $55M | -2% | 3.2M | 17.34 |
|
| Repare Therapeutics Ord (RPTX) | 14.3 | $36M | 3.0M | 12.08 |
|
|
| Cullinan Oncology (CGEM) | 12.1 | $31M | 3.4M | 9.05 |
|
|
| Acelyrin (SLRN) | 9.0 | $23M | -15% | 2.3M | 10.17 |
|
| Orchard Therapeutics Spon Ads New | 5.5 | $14M | +1529% | 12M | 1.14 |
|
| Larimar Therapeutics (LRMR) | 5.3 | $14M | 3.4M | 3.95 |
|
|
| Keros Therapeutics (KROS) | 5.1 | $13M | 408k | 31.88 |
|
|
| Ikena Oncology (IKNA) | 3.7 | $9.4M | +2% | 2.2M | 4.33 |
|
| Ultragenyx Pharmaceutical (RARE) | 3.0 | $7.7M | +152% | 215k | 35.65 |
|
| Compass Therapeutics (CMPX) | 2.2 | $5.6M | 2.8M | 1.97 |
|
|
| Mineralys Therapeutics (MLYS) | 2.1 | $5.4M | NEW | 568k | 9.51 |
|
| Inozyme Pharma (INZY) | 2.1 | $5.3M | +6% | 1.3M | 4.20 |
|
| Syros Pharmaceuticals Com New (SYRS) | 2.0 | $5.1M | +69% | 1.3M | 3.94 |
|
| Blueprint Medicines (BPMC) | 1.8 | $4.7M | NEW | 93k | 50.22 |
|
| Direxion Shs Etf Tr Daily S&p Biotec (LABD) | 1.8 | $4.6M | -30% | 225k | 20.60 |
|
| 2seventy Bio Common Stock (TSVT) | 1.5 | $3.9M | +17% | 1.0M | 3.92 |
|
| Moonlake Immunotherapeutics Class A Ord (MLTX) | 1.3 | $3.4M | NEW | 60k | 57.00 |
|
| Ovid Therapeutics (OVID) | 1.3 | $3.3M | 865k | 3.84 |
|
|
| Sagimet Biosciences Com Ser A (SGMT) | 1.2 | $3.1M | NEW | 349k | 8.80 |
|
| Omega Therapeutics Common Stock (OMGA) | 0.9 | $2.3M | 1.1M | 2.15 |
|
|
| Black Diamond Therapeutics (BDTX) | 0.8 | $2.1M | -4% | 720k | 2.87 |
|
| Rallybio Corp (RLYB) | 0.5 | $1.3M | -28% | 391k | 3.37 |
|
| Disc Medicine (IRON) | 0.5 | $1.2M | -80% | 25k | 46.98 |
|
| Graphite Bio | 0.2 | $573k | 231k | 2.48 |
|
|
| Freeline Therapeutics Hldgs Sponsored Ads | 0.1 | $373k | +299% | 87k | 4.30 |
|
| Precision Biosciences Ord | 0.1 | $207k | -62% | 607k | 0.34 |
|
Past Filings by CHI Advisors
SEC 13F filings are viewable for CHI Advisors going back to 2019
- CHI Advisors 2023 Q3 filed Nov. 13, 2023
- CHI Advisors 2023 Q2 restated filed Aug. 22, 2023
- CHI Advisors 2023 Q2 filed Aug. 11, 2023
- CHI Advisors 2023 Q1 filed May 11, 2023
- CHI Advisors 2022 Q4 filed Feb. 13, 2023
- CHI Advisors 2022 Q3 filed Nov. 9, 2022
- CHI Advisors 2022 Q2 filed Aug. 12, 2022
- CHI Advisors 2022 Q1 filed May 16, 2022
- CHI Advisors 2021 Q4 filed Feb. 11, 2022
- CHI Advisors 2021 Q3 filed Nov. 15, 2021
- CHI Advisors 2021 Q2 filed Aug. 11, 2021
- CHI Advisors 2021 Q1 filed May 14, 2021
- CHI Advisors 2020 Q4 filed Feb. 12, 2021
- CHI Advisors 2020 Q3 filed Nov. 12, 2020
- CHI Advisors 2020 Q2 restated filed Aug. 17, 2020
- CHI Advisors 2020 Q2 filed Aug. 12, 2020